Pharmaron Beijing stock
Price history
+33.10% over the period1 year: from ¥29.52 (November 18, 2025) to ¥39.29 (November 18, 2026), +33.10%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 18, 2026 | ¥39.29 |
| October 30, 2026 | ¥41.37 |
| September 30, 2026 | ¥44.97 |
| August 31, 2026 | ¥43.30 |
| July 31, 2026 | ¥36.80 |
| June 30, 2026 | ¥28.93 |
| May 29, 2026 | ¥25.10 |
| April 30, 2026 | ¥29.31 |
| March 31, 2026 | ¥27.98 |
| February 27, 2026 | ¥29.60 |
| January 30, 2026 | ¥29.68 |
| December 31, 2025 | ¥28.43 |
| November 28, 2025 | ¥28.95 |
| November 18, 2025 | ¥29.52 |
At a glance
The company
Provides pharmaceutical research and development services including drug discovery, chemical manufacturing, clinical research and cell and gene therapy
Latest results
Quarter to September 30, 2026 · EPS ¥0.27 (estimate ¥0.30)
Next event
TickerLandia's take on Pharmaron Beijing
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 42 vs a median of 59 over its last 7 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 42 vs 40 (+7%) in a group of 8.
- Strong point: Earnings stability (89/100 in its group). Weak point: Financial strength (25/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−26.66% from the 52-week high
Analysts · 13 analysts
Average target¥50.40+28.29% vs. price
Buy 9 · Hold 3 · Sell 1 · Buy
TickerLandia Fingerprint: Pharmaron Beijing
Compared with similar companies: very high earnings stability and very strong momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Priceaverage43
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 23.9 51 Price/book 4.49 34 Price/sales 4.77 24 P/E (trailing 12 months) 42.4 58 Forward P/E 28.0 50 Profitabilityaverage42
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 14.0% 42 Net margin 11.1% 53 ROE 10.4% 51 Gross margin 33.7% 14 ROA 4.8% 53 Earnings stabilityvery high89
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.2% 94 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthaverage45
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +11.14% 27 Revenue growth (year over year) +20.90% 51 Earnings growth (year over year) +8.90% 58 Financial strengthlow25
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 10.6 51 Net debt/EBITDAcounts in reverse: lower means more financial strength 1.56 20 Debt/equitycounts in reverse: lower means more financial strength 0.42 26 Current ratio 1.04 3 Dividendaverage46
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 20.4% 36 Consecutive dividend years at least 8 years 72 Dividend yield 0.5% 31 Market momentumvery strong83
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +33.10% 78 Distance from 200-day average +15.28% 88 Riskhigh66
How much the price swings.
Metric Value Position in group Volatility (60 days) 60.9% 81 Maximum drawdown (12 months) 34.0% 51
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Pharmaron Beijing is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Pharmaron Beijing's P/E today is 41.8, below the median of its last 7 fiscal years (58.6; between 25.4 and 81.5 from 2019 to 2025). Pharmaron Beijing's P/E (trailing 12 months): 42.4, +7% against the median of a group of 8 similar companies (39.6).
Compared with 8 similar companies
| Metric | Pharmaron Beijing | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 42.4 | Middle | |
| Forward P/E | 28.0 | Middle | |
| Operating margin | 14.0% | Middle | |
| ROE | 10.4% | Middle | |
| Debt/equity | 0.42 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Pharmaron Beijing. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥4.41B
Latest quarter · Q3 2026
Net income
¥496.93M
Latest quarter · Q3 2026
Quarterly net margin
11.3%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ¥76.36B
- P/E
- 42.4
- EPS
- ¥0.98
- Volume
- 15.32M
- Daily trading
- €245.3M
- Dividend yield
- 0.51%
- Last ex-dividend on July 7, 2026
How Pharmaron Beijing is changing
All resultsRevenue grew 22.4% a year on average over the last 5 years
Operating margin fell from 16.2% to 14.5%
Less cash than profit: free cash flow equal to 19% of net income
Returns
Pharmaron Beijing returns with dividends
¥1,000 invested in Pharmaron Beijing 5 years ago, on November 18, 2021, would be worth ¥499 today with dividends reinvested: −50.14% in total, −13.00% per year. On price alone it would be ¥478 (−52.21%).
| Period | Pharmaron Beijing | ¥1,000 becomes |
|---|---|---|
| 1 month | +2.05% | ¥1,021 |
| 6 months | +49.16% | ¥1,492 |
| Year to date | +38.20% | ¥1,382 |
| 1 year | +33.97% | ¥1,340 |
| 3 years | +17.40% | ¥1,174 |
| 5 years | −50.14% | ¥499 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Pharmaron Beijing: technical analysis
Pharmaron Beijing shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 62.2% below its all-time closing high (¥103.85, August 5, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 42
- Between 30 and 70
- vs 200-session average
- +15.28%
Active signals
The last session opened more than 3% above the previous close.
since November 17, 2026
Support and resistance
Price areas where Pharmaron Beijing has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance¥46.62+18.64%2 touches, last on October 8, 2026
- Last price¥39.29
- Support¥34.96−11.03%3 touches, last on October 19, 2026
- Support¥31.67−19.40%3 touches, last on April 28, 2026
- Support¥29.06−26.04%8 touches, last on March 12, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 60.9%
- Largest fall in the last year
- −34.00%
In session, November 18, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Pharmaron Beijing: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for Pharmaron Beijing has been February: +18.93% on average, positive in 4 years out of 8. The weakest has been November: −4.86% on average, positive in 2 years out of 7.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.06% | +4.40% | 4 of 7 |
| February | +18.93% | +1.13% | 4 of 8 |
| March | −0.99% | −0.42% | 4 of 8 |
| April | −0.60% | +2.37% | 4 of 8 |
| May | +0.38% | +1.20% | 4 of 8 |
| June | +8.40% | +9.10% | 5 of 8 |
| July | +8.39% | +8.76% | 6 of 8 |
| August | +2.26% | +1.08% | 4 of 8 |
| September | +9.36% | +7.89% | 6 of 8 |
| October | +0.72% | −3.84% | 3 of 8 |
| November | −4.86% | −5.69% | 2 of 7 |
| December | −0.22% | −1.80% | 3 of 7 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Pharmaron Beijing and its competitors
Laboratory Services, the first of the five segments through which Pharmaron Beijing Co., Ltd. and its subsidiaries operate, provides chemistry and biological science services for small molecule drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates and cell and gene therapy products. The company also runs small molecule CDMO services, covering API process development and production, formulation and analytical development, alongside clinical research and macromolecular and cell and gene therapy services that span drug discovery through to production.
- Headquarters
- Beijing, China
- Employees
- 25,088
- Founded
- 2004
- Chief executive
- Boliang Lou
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Pharmaron Beijing300759 | $11.45B | 14.0% | 42.4 | +49.16% |
| Sino Biopharmaceutical1177 | $12.49B | 28.2% | 36.7 | +0.57% |
| Haisco Pharmaceutical Group002653 | $9.79B | 21.1% | 50.6 | +4.89% |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | $13.65B | -0.2% | — | −1.27% |
| ALTEOGEN196170 | $9.17B | 47.2% | 97.1 | −38.65% |
| Genscript Biotech1548 | $8.83B | 14.9% | — | +111.76% |
Same industry or related industries, similar size. Compare Pharmaron Beijing with its competitors · Full profile
